Prevalence and Recovery from Newly Onset Anosmia and Ageusia in Covid 19 Patients at our Teritary Care Centre

Kandakure, Vinod Tukaram; Valvi, Harshala R; Khokle, Pradipkumar; More, Madhuri S.; Chouhan, Ritika

doi:10.1007/s12070-021-02540-w

Cited by 10 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Olfactory disorders, either partial or total, were reported in 73% of the population with 8% anosmia. This overall olfactory compromise found in this work did not corroborate with the short-term recovery reported by a multicentric study done in India (85%), France (64%), and Europe (44%), respectively [ 1 , 31 , 32 ].…”

Section: Discussioncontrasting

confidence: 99%

Correlation between Post-COVID-19, Chemosensitive Function, Blood Group, and Oral Health-Related Quality of Life

Sandeepa

Misfer

Alraqdi

et al. 2022

International Journal of Dentistry

View full text Add to dashboard Cite

Background/Purpose. Several studies reported chemosensitive dysfunction in the olfactory and gustatory domains following coronavirus disease 2019 (COVID-19). However, the long-term convalescence period of these sensory functions and associated factors remains unknown. Hence, this study explored the correlation between post-COVID-19 conditions, chemosensitive function, blood group, and oral health-related quality of life. Materials and Methods. A cross-sectional information on demographics, symptomatic disease status, ABO blood group, and oral health-related quality of life (OHRQoL) was collected among 100 patients who were earlier tested positive for COVID-19 reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and were now reporting to the College of Dentistry for routine treatment after recovery. Objective evaluation of olfactory and gustatory disturbances was elicited using the Connecticut Chemosensory Clinical Research Center (CCCRC) test and gustatory function testing. Furthermore, OHRQoL was assessed using Oral Health Impact Profile (OHIP-14). Results. More than half of the patients (62%) had some form of olfactory dysfunction/alteration, and 42% had poor CCCRC scores. About 14% reported ageusia, while 68% reported some form of taste alterations, and 55% reported poor OHRQoL. A statistically significant difference was reported between different ABO blood groups and subjective loss of smell ( p < 0.05 ). The subjective loss of taste, CCCRC score, and dysgeusia were found to be independent of OHIP-14 ( p > 0.05 ), but the taste intensity score was dependent on OHIP 14 ( p < 0.05 ). Moreover, a majority (70.8% and 70.0%) with poor OHIP-14 scores had taste intensity scores of 3 and 4, respectively, while those with moderate (68.4% and 48.6%) OHIP-14 had scored 1 and 2, respectively. Conclusion. Olfactory and gustatory disturbances were found to be a long-term feature in post-COVID-19 patients. The blood group is a predisposing factor for persistent smell alterations in post-COVID-19 patients.

show abstract

Section: Discussioncontrasting

confidence: 99%

Correlation between Post-COVID-19, Chemosensitive Function, Blood Group, and Oral Health-Related Quality of Life

Sandeepa

Misfer

Alraqdi

et al. 2022

International Journal of Dentistry

View full text Add to dashboard Cite

show abstract

“…These 40 studies (reporting on 43 cohorts) were subjected to a meta-analysis (Table ). Fifteen studies reported anosmia prevalence in 18 cohorts with a total of 7247 COVID-19 patients from regions where the D614 virus was dominant: three studies from Kuwait or Singapore − and 12 from India or Pakistan. − We compared such data with the results obtained in 25 studies reporting on 25 cohorts with a total of 9626 South Asian patients from the Indian subcontinent (India and Bangladesh) and Oman, when the G614 virus had become dominant (Table , illustrated in Figure A and B). ,− The differences in results between the two types of cohorts are shown in the forest plots (Figure A). The pooled prevalence of olfactory dysfunction in the same ethnicity (South Asians) in regions with D614 predominance was 5.33% (95% confidence interval, CI = 3.52–8.00%), while in regions with G614 predominance, it was 31.79% (95% CI = 23.26–41.76%) (Figure A, C).…”

Section: Resultsmentioning

confidence: 99%

The D614G Virus Mutation Enhances Anosmia in COVID-19 Patients: Evidence from a Systematic Review and Meta-analysis of Studies from South Asia

Bartheld

Hagen

Butowt

2021

ACS Chem. Neurosci.

View full text Add to dashboard Cite

The prevalence of chemosensory dysfunction in patients with COVID-19 varies greatly between populations. It is unclear whether such differences are due to factors at the level of the human host, or at the level of the coronavirus, or both. At the host level, the entry proteins which allow virus binding and entry have variants with distinct properties, and the frequency of such variants differs between ethnicities. At the level of the virus, the D614G mutation enhances virus entry to the host cell. Since the two virus strains (D614 and G614) coexisted in the first six months of the pandemic in most populations, it has been difficult to distinguish between contributions of the virus and contributions of the host for anosmia. To answer this question, we conducted a systematic review and meta-analysis of studies in South Asian populations when either the D614 or the G614 virus was dominant. We show that populations infected predominantly with the G614 virus had a much higher prevalence of anosmia (pooled prevalence of 31.8%) compared with the same ethnic populations infected mostly with the D614 virus strain (pooled anosmia prevalence of 5.3%). We conclude that the D614G mutation is a major contributing factor that increases the prevalence of anosmia in COVID-19, and that this enhanced effect on olfaction constitutes a previously unrecognized phenotype of the D614G mutation. The new virus strains that have additional mutations on the background of the D614G mutation can be expected to cause a similarly increased prevalence of chemosensory dysfunctions.

show abstract

“…After the rapid spread of coronavirus all over the world with a high incidence of reported ageusia and anosmia in COVID-19 patients and the persistence of those manifestations for an extended period in 13.1% of affected patients [5], [7], [11] a primary concern was drawn to find a safe medical intervention to help in improving the persistent ageusia and anosmia in those patients to improve a person quality of life [8].…”

Section: Discussionmentioning

confidence: 99%

“…Smell and taste dysfunction is more frequent in the initial stages of COVID-19 infection that occur within the first 5 days and may be used as pivotal symptoms in the early diagnosis of the disease [6]. Complete recovery of ageusia and anosmia occurs in most COVID-19 patients with 21 days of infection except few cases that show the persistence of those manifestations for an extended period [7].…”

Section: Introductionmentioning

confidence: 99%

Association between Administration of Systemic Corticosteroids and the Recovery of Olfactory and/or Gustatory Functions in Patients with COVID-19: A Prospective Cohort Study

Gamil

Ismail

Abdou³

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

AIM: This study is a prospective cohort study aimed to assess the effect of systemic corticosteroids administration time in the recovery of gustatory and olfactory sensations dysfunction (ageusia and anosmia) in COVID-19 patients. MATERIALS AND METHODS: Sixty-seven COVID-19 patients with symptoms of ageusia and anosmia were recruited (that their COVID infection was confirmed using polymerase chain reaction). Daily 10 mg of systemic corticosteroids were prescribed in the 1st week and then reduced to 5 mg in the 2nd week to all the patients to observe taste and smell sensation recovery. All data were recorded and then analyzed. Patients were then grouped into two groups (early and late groups) according to the duration of their taste and smell dysfunction. RESULTS: Regression analysis showed that early corticosteroid administration resulted in a significant decrease in recovery time of ageusia and anosmia (0.27 [0.2–0.35], p < 0.001). Patients in the early administration group (<1 week) showed faster improvement in regaining taste and smell functions than in the late administration group (>1 week) with significant difference (p < 0.001). CONCLUSIONS: The use of systemic corticosteroids in early phases of covid-19 infection help in faster recovery of ageusia and anosmia.

show abstract

Prevalence and Recovery from Newly Onset Anosmia and Ageusia in Covid 19 Patients at our Teritary Care Centre

Cited by 10 publications

References 36 publications

Correlation between Post-COVID-19, Chemosensitive Function, Blood Group, and Oral Health-Related Quality of Life

Correlation between Post-COVID-19, Chemosensitive Function, Blood Group, and Oral Health-Related Quality of Life

The D614G Virus Mutation Enhances Anosmia in COVID-19 Patients: Evidence from a Systematic Review and Meta-analysis of Studies from South Asia

Association between Administration of Systemic Corticosteroids and the Recovery of Olfactory and/or Gustatory Functions in Patients with COVID-19: A Prospective Cohort Study

Contact Info

Product

Resources

About